$PBT

PERMIAN BASIN ROYALTY TRUST (PBT): Results of Operations and Financial Condition

PERMIAN BASIN ROYALTY TRUST (PBT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pbt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Permian Basin Royalty Trust PERMIAN BASIN ROYALTY TRUST ANNOUNCES JULY CASH DISTRIBUTION AND EXCESS COST POSITION ON WADDELL RANCH PROPERTIES DALLAS, Texas, July 21, 2026 – Argent Trust Company, as Trustee of the Permian Basin

Original reporting
Published Jul 21, 2026, 3:43 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 21, 2026, 3:48 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$PBT
Neutral
medium confidence
Mentioned
$PBT
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PBTNeutralMed
01

Why it matters

The release sets the cash distribution amount and clarifies that Waddell Ranch had an excess-cost position in June, meaning no proceeds were included in the July distribution; future distributions require recovery of excess costs before NPI proceeds can be distributed.

02

Market read

Traders can update near-term income expectations from the declared per-unit distribution and reassess downside risk from continued Waddell Ranch excess costs.

03

What to watch

Operator reporting is quarterly for NPI proceeds, so the next 10-Q/10-K could introduce delayed but meaningful cash-flow updates that are not visible in this monthly distribution alone.

Relevance 7/10Novelty 7/10Timing: distribution payable Aug. 14, 2026, record date July 31, 2026

Background

PBT is a royalty trust whose unit distributions depend on net profits interest (NPI) proceeds from underlying properties, with some operator data delivered quarterly.

Company-level read

Ticker impact

$PBTNeutralMedium confidence
Context

Permian Basin Royalty Trust declares an Aug. 14 cash distribution of $0.043566/unit and notes Waddell Ranch remains in an excess-cost position.

Expected impact

Near-term trading likely tracks distribution expectations, but the stated lack of June Waddell proceeds and continued excess costs may cap upside until future recoveries are reported.

Evidence & confidence

The filing provides a concrete per-unit distribution and explicitly states no Waddell proceeds were received for June, implying future distributions depend on recovering excess costs before any NPI proceeds flow through.

Market effects

Highlights how royalty trusts can experience distribution volatility when production costs exceed gross proceeds in specific property pools.

None material beyond Permian-area oil and gas pricing sensitivity referenced in the release.

Limited; primarily idiosyncratic to PBT’s underlying royalty interests and operator reporting cadence.

Counterpoint

The distribution increased versus the prior month due to a specific settlement payment, so the market may be able to look through Waddell excess costs if Texas Royalty cash flows remain supportive.

Key entities

  • PERMIAN BASIN ROYALTY TRUST

    Trust declaring the July cash distribution and reporting property-level production, pricing, and cost/revenue outcomes.

  • Argent Trust Company

    Trustee that declared the cash distribution and provides the operational financial condition update.

  • Blackbeard Operating LLC

    Operator providing production, pricing, and cost information used to calculate NPI proceeds for Waddell Ranch.

  • SoftVest, L.P.

    Filed a Schedule 13D describing a preliminary non-binding term sheet for a potential business combination involving Trust assets and Blackbeard holdings.

Related articles

$PBTMed

PERMIAN BASIN ROYALTY TRUST (PBT): Results of Operations and Financial Condition

PERMIAN BASIN ROYALTY TRUST (PBT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pbt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Permian Basin Royalty Trust PERMIAN BASIN ROYALTY TRUST ANNOUNCES AUGUST CASH DISTRIBUTION AND EXCESS COST POSITION ON WADDELL RANCH PROPERTIES DALLAS, Texas, August 21, 2026 – Argent Trust Company, as Trustee of the Permian B

$PBTMed

PERMIAN BASIN ROYALTY TRUST ANNOUNCES NOTICE OF COMBINATION AGREEMENT BETWEEN SOFTVEST AND BLACKBEARD WITH RESPECT TO THE TRUST

Permian Basin Royalty Trust (NYSE: PBT) said it was notified by unitholder SoftVest that SoftVest and affiliates entered a definitive combination agreement with Blackbeard to combine Trust assets and Blackbeard oil and gas interests to form PBT Land and Minerals, Inc. Unitholder approval is required, with a special meeting requested by holders with over 15% of units.

$PBTMed

PERMIAN BASIN ROYALTY TRUST (PBT): Results of Operations and Financial Condition

PERMIAN BASIN ROYALTY TRUST (PBT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pbt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Permian Basin Royalty Trust PERMIAN BASIN ROYALTY TRUST ANNOUNCES JUNE CASH DISTRIBUTION, EXCESS COST POSITION ON WADDELL RANCH PROPERTIES AND SOFTVEST PROPOSAL DALLAS, Texas, June 18, 2026 – Argent Trust Company, as Trustee o

$GILDHighAI 8/10

Gilead’s Core Business Is Accelerating, But Will Its $11 Billion Pipeline Bet Pay Off?

Gilead Sciences (GILD) reported Q2 2026 with double-digit growth in commercial portfolio sales, but posted a significant loss due to $11.2B in R&D expenses from acquisitions. HIV sales rose 12% to $5.7B, while non-HIV areas like liver disease and cancer treatments also showed growth. The company raised its 2026 sales guidance and made strategic acquisitions, but faces risks from clinical development and financial obligations.

$ABBVMedAI 8/10

AbbVie’s Humira Replacement Strategy Is Working, But Could Growth Be Too Concentrated?

AbbVie (NYSE:ABBV) reported Q2 2026 revenue of $16.99B, up 10.2%, driven by immunology and neuroscience. Skyrizi and Rinvoq revenues grew 24.4% and 24.5% respectively, offsetting Humira's 35.9% decline. However, concentration risk exists as these two products made up 47% of revenue. Oncology and aesthetics showed weaker performance, with oncology revenue down 1.5%. Adjusted EPS rose 22.9% to $3.65.